Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1984 Oct;50(4):471–478. doi: 10.1038/bjc.1984.203

Differences in tumour necrosis factor productive ability among rodents.

K Haranaka, N Satomi, A Sakurai
PMCID: PMC1976898  PMID: 6386027

Abstract

Large differences in tumour necrosis factor (TNF) productive ability 05337257erved among various strains of mice. DDY, CD-1, ICR and DBA/2 mice could produce a high titre of TNF activity, whereas Balb/c, C3H/HeJms and A/J mice produced a low titre of TNF activity. Administration of 200 micrograms/mouse of LPS to some strains of mice, i.e. DDD and C57B1/6J resulted in good production of TNF. ICR nu/nu mice produced the highest TNF activity among the nude mice. Balb/c nu/nu and DDD nu/nu mice exhibited very low titres of TNF activity. Nude mice required a rather higher dose of the priming agent, Propionibacterium acnes, than heterozygote littermates. Although it is commonly accepted that dual stimulation is necessary for TNF production, TNF activity was detected without the priming agent in SD rats and Golden hamsters by single injection of LPS. In these animals, much higher TNF production was observed after Propionibacterium acnes treatment than after a single injection of LPS. Large differences in TNF productive ability also existed among strains of rats. Although all animals receiving priming agents revealed hyperplasia of reticuloendothelial system, the sensitivity of the animals to LPS is considered to be the most important factor in their TNF productive ability.

Full text

PDF
471

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALGIRE G. H., LEGALLAIS F. Y., ANDERSON B. F. Vascular reactions of normal and malignant tissues in vivo. V. The rôle of hypotension in the action of a bacterial polysaccharide on tumors. J Natl Cancer Inst. 1952 Jun;12(6):1279–1295. [PubMed] [Google Scholar]
  2. Boraschi D., Meltzer M. S. Defective tumoricidal capacity of macrophages from A/J mice. I. Characterization of the macrophage cytotoxic defect after in vivo and in vitro activation stimuli. J Immunol. 1979 Apr;122(4):1587–1591. [PubMed] [Google Scholar]
  3. Boraschi D., Meltzer M. S. Defective tumoricidal capacity of macrophages from A/J mice. II. Comparison of the macrophage cytotoxic defect of A/J mice with that of lipid A-unresponsive C3H/HeJ mice. J Immunol. 1979 Apr;122(4):1592–1597. [PubMed] [Google Scholar]
  4. Boraschi D., Meltzer M. S. Defective tumoricidal capacity of macrophages from A/J mice. III. Genetic analysis of the macrophage defect. J Immunol. 1980 Mar;124(3):1050–1053. [PubMed] [Google Scholar]
  5. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gorecka-Tisera A., Proctor J. W., Yamamura Y., Harnaha J., Meinert K. Dose, route, and time dependence of serum lysozyme and antitumor activity following administration of glucan, Corynebacterium parvum, pyran, or lipopolysaccharide to mice. J Natl Cancer Inst. 1981 Oct;67(4):911–915. [PubMed] [Google Scholar]
  7. Haranaka K., Satomi N. Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro. Jpn J Exp Med. 1981 Jun;51(3):191–194. [PubMed] [Google Scholar]
  8. Matthews N. Tumour-necrosis factor from the rabbit. II. Production by monocytes. Br J Cancer. 1978 Aug;38(2):310–315. doi: 10.1038/bjc.1978.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Matthews N., Watkins J. F. Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties. Br J Cancer. 1978 Aug;38(2):302–309. doi: 10.1038/bjc.1978.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Männel D. N., Moore R. N., Mergenhagen S. E. Macrophages as a source of tumoricidal activity (tumor-necrotizing factor). Infect Immun. 1980 Nov;30(2):523–530. doi: 10.1128/iai.30.2.523-530.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. OLD L. J., CLARKE D. A., BENACERRAF B., GOLDSMITH M. The reticuloendothelial system and the neoplastic process. Ann N Y Acad Sci. 1960 Jun 21;88:264–280. doi: 10.1111/j.1749-6632.1960.tb20026.x. [DOI] [PubMed] [Google Scholar]
  12. Old L. J. Tumor necrosis factor. Clin Bull. 1976;6(3):118–120. [PubMed] [Google Scholar]
  13. Piessens W. F., Churchill W. H., Jr, David Macrophages activated in vitro with lymphocyte mediators kill neoplastic but not normal cells. J Immunol. 1975 Jan;114(1 Pt 2):293–299. [PubMed] [Google Scholar]
  14. Ribi E. E., Granger D. L., Milner K. C., Strain S. M. Tumor regression caused by endotoxins and mycobacterial fractions. J Natl Cancer Inst. 1975 Nov;55(5):1253–1257. doi: 10.1093/jnci/55.5.1253. [DOI] [PubMed] [Google Scholar]
  15. SUTER E., ULLMAN G. E., HOFFMAN R. G. Sensitivity of mice to endotoxin after vaccination with BCG (Bacillus Calmette-Guérin). Proc Soc Exp Biol Med. 1958 Oct;99(1):167–169. doi: 10.3181/00379727-99-24282. [DOI] [PubMed] [Google Scholar]
  16. Satomi N., Haranaka K., Kunii O. Research on the production site of tumor necrosis factor (TNF). Jpn J Exp Med. 1981 Dec;51(6):317–322. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES